Kiora Pharmaceuticals Inc (KPRX): Total Liabilities
$8.13M
As of 2025-12-31
$6.92M
As of 2026-06-30
+3.8%
3-year compound annual growth
+7.8%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $8.13M | -24.2% | 2026-03-25, Balance as of period end |
| 2024-12-31 | $10.72M | +41.1% | 2026-03-25, Balance as of period end |
| 2023-12-31 | $7.60M | +4.6% | 2025-03-25, Balance as of period end |
| 2022-12-31 | $7.27M | +31.0% | 2024-03-25, Balance as of period end |
| 2021-12-31 | $5.55M | -0.4% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $5.57M | n/c | 2022-07-07, Balance as of period end |
| 2019-12-31 | $3.49M | -34.7% | 2021-03-25, Balance as of period end |
| 2018-12-31 | $5.34M | -67.1% | 2020-03-04, Balance as of period end |
| 2017-12-31 | $16.23M | +61.4% | 2019-03-01, Balance as of period end |
| 2016-12-31 | $10.06M | +194.1% | 2018-03-02, Balance as of period end |
| 2015-12-31 | $3.42M | n/a | 2017-02-23, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Kiora Pharmaceuticals Inc (KPRX) | 2025-12-31 | $8.13M | -24.2% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $71.53B | -6.1% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $10.78M | -5.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $121.39B | -2.8% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $117.67B | +8.3% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $99.59M | +24.7% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $7.00M | +0.4% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | $3.14M | -44.7% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $241.54M | -9.5% |
Compare KPRX, BMY, TXMD, PFE side by side · Screen every company in Pharmaceutical Preparations ↗